Apixaban has demonstrated superiority over rivaroxaban when used in patients with non-valvular atrial fibrillation (Press release)

Abstract

References

1. Fralick M., Colacci M., Schneeweiss S. et al. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med. 2020;172(7):463–73. DOI: 10.7326/M19–2522.
2. Lip G.Y., Nieuwlaat R., Pisters R. et al. Refining clinical risk stratification for predicting troke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72. DOI: 10.1378/chest.09–1584.